![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CHRD |
Gene summary for CHRD |
![]() |
Gene information | Species | Human | Gene symbol | CHRD | Gene ID | 8646 |
Gene name | chordin | |
Gene Alias | CHRD | |
Cytomap | 3q27.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | E7ESX1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8646 | CHRD | HCC1_Meng | Human | Liver | HCC | 3.88e-26 | 6.41e-02 | 0.0246 |
8646 | CHRD | HCC2 | Human | Liver | HCC | 3.81e-11 | 2.32e+00 | 0.5341 |
8646 | CHRD | S014 | Human | Liver | HCC | 2.07e-17 | 9.07e-01 | 0.2254 |
8646 | CHRD | S015 | Human | Liver | HCC | 1.29e-26 | 1.36e+00 | 0.2375 |
8646 | CHRD | S016 | Human | Liver | HCC | 4.30e-34 | 1.19e+00 | 0.2243 |
8646 | CHRD | S028 | Human | Liver | HCC | 1.19e-05 | 3.60e-01 | 0.2503 |
8646 | CHRD | S029 | Human | Liver | HCC | 6.50e-03 | 3.52e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
GO:000164911 | Liver | HCC | osteoblast differentiation | 115/7958 | 229/18723 | 1.08e-02 | 3.99e-02 | 115 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:000150315 | Oral cavity | LP | ossification | 123/4623 | 408/18723 | 6.55e-03 | 3.84e-02 | 123 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHRD | SNV | Missense_Mutation | novel | c.1002G>C | p.Leu334Phe | p.L334F | Q9H2X0 | protein_coding | deleterious(0.01) | possibly_damaging(0.903) | TCGA-55-7727-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CHRD | SNV | Missense_Mutation | c.247N>C | p.Glu83Gln | p.E83Q | Q9H2X0 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-55-7995-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
CHRD | SNV | Missense_Mutation | c.1448N>C | p.Gly483Ala | p.G483A | Q9H2X0 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CHRD | SNV | Missense_Mutation | novel | c.1927N>A | p.Gly643Arg | p.G643R | Q9H2X0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-69-7974-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CHRD | SNV | Missense_Mutation | c.406N>G | p.Pro136Ala | p.P136A | Q9H2X0 | protein_coding | tolerated(0.25) | benign(0) | TCGA-73-4668-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | pemetrexed | PD | |
CHRD | SNV | Missense_Mutation | c.2573N>A | p.Pro858His | p.P858H | Q9H2X0 | protein_coding | tolerated(0.4) | possibly_damaging(0.547) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
CHRD | SNV | Missense_Mutation | novel | c.2176T>C | p.Cys726Arg | p.C726R | Q9H2X0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CHRD | SNV | Missense_Mutation | novel | c.2702N>T | p.Arg901Ile | p.R901I | Q9H2X0 | protein_coding | tolerated(0.06) | benign(0.115) | TCGA-86-7711-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
CHRD | SNV | Missense_Mutation | c.2279C>A | p.Pro760His | p.P760H | Q9H2X0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
CHRD | SNV | Missense_Mutation | rs749454000 | c.1916G>A | p.Gly639Glu | p.G639E | Q9H2X0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |